Corcept Therapeutics traded at $39.87 this Friday January 30th, decreasing $4.74 or 10.63 percent since the previous trading session. Looking back, over the last four weeks, Corcept Therapeutics lost 14.57 percent. Over the last 12 months, its price fell by 40.42 percent. Looking ahead, we forecast Corcept Therapeutics to be priced at 38.64 by the end of this quarter and at 35.18 in one year, according to Trading Economics global macro models projections and analysts expectations.
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.